- Home
- NCDL vs GYRE Comparison
NCDL vs GYRE Comparison
Compare NCDL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCDL
- GYRE
- Stock Information
- Founded
- NCDL 2019
- GYRE 2002
- Country
- NCDL United States
- GYRE United States
- Employees
- NCDL N/A
- GYRE N/A
- Industry
- NCDL
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- NCDL
- GYRE Health Care
- Exchange
- NCDL NYSE
- GYRE Nasdaq
- Market Cap
- NCDL 770.8M
- GYRE 897.1M
- IPO Year
- NCDL N/A
- GYRE N/A
- Fundamental
- Price
- NCDL $16.69
- GYRE $8.07
- Analyst Decision
- NCDL Hold
- GYRE
- Analyst Count
- NCDL 3
- GYRE 0
- Target Price
- NCDL $15.75
- GYRE N/A
- AVG Volume (30 Days)
- NCDL 195.6K
- GYRE 412.5K
- Earning Date
- NCDL 08-06-2025
- GYRE 08-12-2025
- Dividend Yield
- NCDL 10.89%
- GYRE N/A
- EPS Growth
- NCDL N/A
- GYRE N/A
- EPS
- NCDL N/A
- GYRE 0.02
- Revenue
- NCDL N/A
- GYRE $100,643,000.00
- Revenue This Year
- NCDL N/A
- GYRE $21.04
- Revenue Next Year
- NCDL N/A
- GYRE $89.64
- P/E Ratio
- NCDL N/A
- GYRE $100.77
- Revenue Growth
- NCDL N/A
- GYRE N/A
- 52 Week Low
- NCDL $14.21
- GYRE $6.11
- 52 Week High
- NCDL $18.01
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- NCDL 67.24
- GYRE 43.87
- Support Level
- NCDL $16.16
- GYRE $7.99
- Resistance Level
- NCDL $16.85
- GYRE $8.55
- Average True Range (ATR)
- NCDL 0.26
- GYRE 0.64
- MACD
- NCDL 0.05
- GYRE -0.05
- Stochastic Oscillator
- NCDL 83.16
- GYRE 28.82
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.